LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

Y. M. Whang, Serkin Park, I. A. Trenary, R. A. Egnatchik, J. P. Fessel, J. M. Kaufman, D. P. Carbone, J. D. Young

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate-activated protein kinase (AMPK) signaling confers sensitivity to metabolic inhibition or stress-induced mitochondrial insults. We tested the hypothesis that loss of LKB1 sensitizes NSCLC cells to energetic stress induced by treatment with erlotinib. LKB1-deficient cells exhibited enhanced sensitivity to erlotinib in vitro and in vivo that was associated with alterations in energy metabolism and mitochondrial dysfunction. Loss of LKB1 expression altered the cellular response to erlotinib treatment, resulting in impaired ATP homeostasis and an increase in reactive oxygen species. Furthermore, erlotinib selectively blocked mammalian target of rapamycin signaling, inhibited cell growth and activated apoptosis in LKB1-deficient cells. Erlotinib treatment also induced AMPK activation despite loss of LKB1 expression, which was partially reduced by the application of a calcium/calmodulin-dependent protein kinase kinase 2 inhibitor (STO-609) or calcium chelator (BAPTA-AM). These findings may have significant implications for the design of novel NSCLC treatments that target dysregulated metabolic and signaling pathways in LKB1-deficient tumors.

Original languageEnglish
Pages (from-to)856-866
Number of pages11
JournalOncogene
Volume35
Issue number7
DOIs
Publication statusPublished - 2016 Feb 18
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Adenosine Monophosphate
Protein Kinases
Calcium-Calmodulin-Dependent Protein Kinase Kinase
Therapeutics
Protein-Serine-Threonine Kinases
Sirolimus
Metabolic Networks and Pathways
Energy Metabolism
Reactive Oxygen Species
Neoplasms
Homeostasis
Adenosine Triphosphate
Erlotinib Hydrochloride
Apoptosis
Growth

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Whang, Y. M., Park, S., Trenary, I. A., Egnatchik, R. A., Fessel, J. P., Kaufman, J. M., ... Young, J. D. (2016). LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. Oncogene, 35(7), 856-866. https://doi.org/10.1038/onc.2015.140

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. / Whang, Y. M.; Park, Serkin; Trenary, I. A.; Egnatchik, R. A.; Fessel, J. P.; Kaufman, J. M.; Carbone, D. P.; Young, J. D.

In: Oncogene, Vol. 35, No. 7, 18.02.2016, p. 856-866.

Research output: Contribution to journalArticle

Whang, YM, Park, S, Trenary, IA, Egnatchik, RA, Fessel, JP, Kaufman, JM, Carbone, DP & Young, JD 2016, 'LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells', Oncogene, vol. 35, no. 7, pp. 856-866. https://doi.org/10.1038/onc.2015.140
Whang, Y. M. ; Park, Serkin ; Trenary, I. A. ; Egnatchik, R. A. ; Fessel, J. P. ; Kaufman, J. M. ; Carbone, D. P. ; Young, J. D. / LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. In: Oncogene. 2016 ; Vol. 35, No. 7. pp. 856-866.
@article{384123e4ad5f4c49a7b120df0a7e1325,
title = "LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells",
abstract = "The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30{\%} of patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate-activated protein kinase (AMPK) signaling confers sensitivity to metabolic inhibition or stress-induced mitochondrial insults. We tested the hypothesis that loss of LKB1 sensitizes NSCLC cells to energetic stress induced by treatment with erlotinib. LKB1-deficient cells exhibited enhanced sensitivity to erlotinib in vitro and in vivo that was associated with alterations in energy metabolism and mitochondrial dysfunction. Loss of LKB1 expression altered the cellular response to erlotinib treatment, resulting in impaired ATP homeostasis and an increase in reactive oxygen species. Furthermore, erlotinib selectively blocked mammalian target of rapamycin signaling, inhibited cell growth and activated apoptosis in LKB1-deficient cells. Erlotinib treatment also induced AMPK activation despite loss of LKB1 expression, which was partially reduced by the application of a calcium/calmodulin-dependent protein kinase kinase 2 inhibitor (STO-609) or calcium chelator (BAPTA-AM). These findings may have significant implications for the design of novel NSCLC treatments that target dysregulated metabolic and signaling pathways in LKB1-deficient tumors.",
author = "Whang, {Y. M.} and Serkin Park and Trenary, {I. A.} and Egnatchik, {R. A.} and Fessel, {J. P.} and Kaufman, {J. M.} and Carbone, {D. P.} and Young, {J. D.}",
year = "2016",
month = "2",
day = "18",
doi = "10.1038/onc.2015.140",
language = "English",
volume = "35",
pages = "856--866",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

AU - Whang, Y. M.

AU - Park, Serkin

AU - Trenary, I. A.

AU - Egnatchik, R. A.

AU - Fessel, J. P.

AU - Kaufman, J. M.

AU - Carbone, D. P.

AU - Young, J. D.

PY - 2016/2/18

Y1 - 2016/2/18

N2 - The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate-activated protein kinase (AMPK) signaling confers sensitivity to metabolic inhibition or stress-induced mitochondrial insults. We tested the hypothesis that loss of LKB1 sensitizes NSCLC cells to energetic stress induced by treatment with erlotinib. LKB1-deficient cells exhibited enhanced sensitivity to erlotinib in vitro and in vivo that was associated with alterations in energy metabolism and mitochondrial dysfunction. Loss of LKB1 expression altered the cellular response to erlotinib treatment, resulting in impaired ATP homeostasis and an increase in reactive oxygen species. Furthermore, erlotinib selectively blocked mammalian target of rapamycin signaling, inhibited cell growth and activated apoptosis in LKB1-deficient cells. Erlotinib treatment also induced AMPK activation despite loss of LKB1 expression, which was partially reduced by the application of a calcium/calmodulin-dependent protein kinase kinase 2 inhibitor (STO-609) or calcium chelator (BAPTA-AM). These findings may have significant implications for the design of novel NSCLC treatments that target dysregulated metabolic and signaling pathways in LKB1-deficient tumors.

AB - The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate-activated protein kinase (AMPK) signaling confers sensitivity to metabolic inhibition or stress-induced mitochondrial insults. We tested the hypothesis that loss of LKB1 sensitizes NSCLC cells to energetic stress induced by treatment with erlotinib. LKB1-deficient cells exhibited enhanced sensitivity to erlotinib in vitro and in vivo that was associated with alterations in energy metabolism and mitochondrial dysfunction. Loss of LKB1 expression altered the cellular response to erlotinib treatment, resulting in impaired ATP homeostasis and an increase in reactive oxygen species. Furthermore, erlotinib selectively blocked mammalian target of rapamycin signaling, inhibited cell growth and activated apoptosis in LKB1-deficient cells. Erlotinib treatment also induced AMPK activation despite loss of LKB1 expression, which was partially reduced by the application of a calcium/calmodulin-dependent protein kinase kinase 2 inhibitor (STO-609) or calcium chelator (BAPTA-AM). These findings may have significant implications for the design of novel NSCLC treatments that target dysregulated metabolic and signaling pathways in LKB1-deficient tumors.

UR - http://www.scopus.com/inward/record.url?scp=84958744475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958744475&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.140

DO - 10.1038/onc.2015.140

M3 - Article

C2 - 26119936

AN - SCOPUS:84958744475

VL - 35

SP - 856

EP - 866

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 7

ER -